207 related articles for article (PubMed ID: 27408946)
21. New therapy update. Inspra (eplerenone tablets).
Kloner RA
Congest Heart Fail; 2003; 9(6):341-2. PubMed ID: 14688507
[No Abstract] [Full Text] [Related]
22. A comparison of the aldosterone-blocking agents eplerenone and spironolactone.
Karagiannis A; Athyros VG; Mikhailidis DP
Clin Cardiol; 2009 Apr; 32(4):230. PubMed ID: 19353701
[No Abstract] [Full Text] [Related]
23. Eplerenone--a novel selective aldosterone blocker.
Zillich AJ; Carter BL
Ann Pharmacother; 2002 Oct; 36(10):1567-76. PubMed ID: 12243608
[TBL] [Abstract][Full Text] [Related]
24. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
25. Adrenal gland inclusions in patients treated with aldosterone antagonists (Spironolactone/Eplerenone): incidence, morphology, and ultrastructural findings.
Patel KA; Calomeni EP; Nadasdy T; Zynger DL
Diagn Pathol; 2014 Aug; 9():147. PubMed ID: 25108298
[TBL] [Abstract][Full Text] [Related]
26. The risks and benefits of aldosterone antagonists.
Sica DA
Curr Heart Fail Rep; 2005 Aug; 2(2):65-71. PubMed ID: 16036053
[TBL] [Abstract][Full Text] [Related]
27. Mineralocorticoid receptor antagonists: their use and differentiation in Japan.
Sato A
Hypertens Res; 2013 Mar; 36(3):185-90. PubMed ID: 23171954
[TBL] [Abstract][Full Text] [Related]
28. [Eplerenone in resistant hypertension with previous spironolactone intolerance].
Antonio Costa J; Rodilla E; Pérez-Lahiguera F; María Pascual J
Med Clin (Barc); 2009 May; 132(19):756-7. PubMed ID: 19243793
[No Abstract] [Full Text] [Related]
29. What is the role of aldosterone excess in resistant hypertension and how should it be investigated and treated?
Sica DA
Curr Cardiol Rep; 2011 Dec; 13(6):520-6. PubMed ID: 21993610
[TBL] [Abstract][Full Text] [Related]
30. The EPHESUS trial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Eplerenone Post-AMI Heart Failure Efficacy and Survival Study.
Pitt B; Williams G; Remme W; Martinez F; Lopez-Sendon J; Zannad F; Neaton J; Roniker B; Hurley S; Burns D; Bittman R; Kleiman J
Cardiovasc Drugs Ther; 2001 Jan; 15(1):79-87. PubMed ID: 11504167
[No Abstract] [Full Text] [Related]
31. SFE/SFHTA/AFCE consensus on primary aldosteronism, part 7: Medical treatment of primary aldosteronism.
Pechère-Bertschi A; Herpin D; Lefebvre H
Ann Endocrinol (Paris); 2016 Jul; 77(3):226-34. PubMed ID: 27315759
[TBL] [Abstract][Full Text] [Related]
32. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
Moore TD; Nawarskas JJ; Anderson JR
Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
[TBL] [Abstract][Full Text] [Related]
33. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL
Arch Intern Med; 2003 Jul; 163(13):1543-8. PubMed ID: 12860576
[TBL] [Abstract][Full Text] [Related]
34. Aldosterone receptor blockade: a therapy resurrected.
Sica DA
Heart Dis; 2003; 5(2):85-8. PubMed ID: 12713674
[No Abstract] [Full Text] [Related]
35. Review article: eplerenone: an underused medication?
Abuannadi M; O'Keefe JH
J Cardiovasc Pharmacol Ther; 2010 Dec; 15(4):318-25. PubMed ID: 20876342
[TBL] [Abstract][Full Text] [Related]
36. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone.
Hu X; Li S; McMahon EG; Lala DS; Rudolph AE
Mini Rev Med Chem; 2005 Aug; 5(8):709-18. PubMed ID: 16101407
[TBL] [Abstract][Full Text] [Related]
37. Effects of eplerenone, a selective mineralocorticoid receptor antagonist, on clinical and experimental salt-sensitive hypertension.
Takeda Y
Hypertens Res; 2009 May; 32(5):321-4. PubMed ID: 19300447
[TBL] [Abstract][Full Text] [Related]
38. The use of aldosterone receptor blockers in the treatment of hypertension.
Weinberger MH
J Clin Hypertens (Greenwich); 2004 Nov; 6(11):632-5. PubMed ID: 15538096
[TBL] [Abstract][Full Text] [Related]
39. Eplerenone relieves spironolactone-induced painful gynaecomastia in a patient with primary aldosteronism.
Karagiannis A; Tziomalos K; Kakafika A; Florentin M; Athyros VG
Nephrol Dial Transplant; 2007 Jan; 22(1):293. PubMed ID: 17018542
[No Abstract] [Full Text] [Related]
40. Progress in primary aldosteronism: mineralocorticoid receptor antagonists and management of primary aldosteronism in pregnancy.
Riester A; Reincke M
Eur J Endocrinol; 2015 Jan; 172(1):R23-30. PubMed ID: 25163723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
